Business Wire

Workato Named a Leader in the 2023 Gartner® Magic Quadrant™ for iPaaS

3.2.2023 18:15:00 EET | Business Wire | Press release

Share

Workato, the leading enterprise automation and integration platform, announced today that it has again been recognised as a Leader in the 2023 Gartner® Magic Quadrant™ for Integration Platform as a Service. Workato has been named a Leader all five years it has participated in the Gartner® Magic Quadrant™ for iPaaS. The report evaluated 16 total software vendors and placed Workato in the Leaders quadrant for its ability to execute, and completeness of vision. For us, Workato’s position within the Leaders quadrant signals one of the best positionings of a modern iPaaS to date.

The Workato platform enables enterprises to automate their business processes across the entire organization by integrating their applications, data, and experiences. Designed with best-in-class security and governance, scalability, performance, and availability, Workato’s low-code, no-code platform makes it easy for IT and business teams to integrate their applications and automate their processes, drawing from thousands of automation “recipes” built by the Workato community. With Workato’s democratized approach to automation and integration, business technologists are empowered to fuel their organization’s digital transformation.

“We founded Workato with the mission to rethink integration. This year’s Magic Quadrant for iPaaS highlights a significant change in the market's future and we are honored to be recognized as a Leader,” said Vijay Tella, Co-founder, and CEO of Workato. “Automation and integration is one of the top priorities for C-Suite, with a growing backlog of these projects across the enterprise. Workato’s breadth of features paired with strong security and governance capabilities enable organizations of any size to democratize complex projects enabling both IT and business technologist teams to drive business outcomes at scale across their enterprise. It's exciting to see Workato with the highest customer experience ratings on Gartner Peer Review citing Workato's ease of use and high quality of support. We are proud that Workato's mission and execution have pushed us to the forefront over the last 12 months."

In addition to being named a Leader in the report, Workato has the highest overall rating, 4.9 out of 5, on Gartner Peer InsightsTM and the most 5-star reviews, 234 out of 264, as of January 25, 2023. Customers that have shared their experience of using Workato in the past year include:

“With Workato, we are able to seamlessly integrate the data in our HCM system with other applications to accelerate and improve the hiring and onboarding process and help ensure our new hires are successful in their roles,” said Arlen Thurber, Senior Business & Systems Engineer at DataStax. “We’ve automated 6,500 emails for a time savings of 99.9%. Workato made it easy to integrate our people data so we could automate a time-consuming and distracting process without compromising our high standards for management and security.”

Gartner Magic Quadrant™ research methodology provides a graphical competitive positioning of four types of technology providers in fast-growing markets: Leaders, Visionaries, Niche Players and Challengers. According to the 2023 report for iPaaS, Workato is recognized in the Leader quadrant, which is classified as having executed well against its current vision of today and being well positioned for tomorrow.

This announcement follows a year of milestones for the company which includes being recognized as a CNBC Disruptor, launching the first Automate World Tour, and releasing two industry reports, The Work Automation Index and the vendor-neutral State of Business Technology Report. In addition to being named in Gartner, Workato also secured placement on this year’s Deloitte Technology Fast 500 and the Forbes Cloud 100 rankings.

Access a complimentary copy of the Gartner report and learn more about Workato at https://www.workato.com.

*Source: Gartner, Magic Quadrant for Integration Platform as a Service, Worldwide, Keith Guttridge, Andrew Comes, Saikat Ray, et al., January 24, 2023.

Gartner does not endorse any vendor, product, or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designations. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a registered trademark and service mark, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

About Workato

As a leader in Enterprise Automation, Workato enables IT and business teams to drive business outcomes at scale by automating their processes and integrating their data, apps, and user experience across their entire organization with best-in-class security and governance. Further, Workato can also be embedded by SaaS providers to address their product integration needs. Over 17,000 of the world's top brands, like Payless, Broadcom, Helen of Troy, Logitech, Atlassian, Autodesk, Hubspot, and Toast, choose Workato to accelerate their business transformation initiatives. Headquartered in Mountain View, Calif., Workato is backed by Altimeter Capital, Battery Ventures, Insight Venture Partners, Tiger Global, and Redpoint Ventures. For more information, visit workato.com or connect with us on social media:

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Joseph Hollister
Corporate Communications Manager
joseph.hollister@workato.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye